This gene was found altered in approximately 10% of patients with HNSCC, and they proposed that patients with loss-of-function NSD1 mutations should be considered a distinct clinical subclass of HPV-negative HNSCC, with increased cisplatin sensitivity (39). This evidence concerns the gene NSD1 and head and neck squamous cell carcinoma.